US2012252761A1PendingUtilityA1
Kinase inhibitors
Est. expiryApr 18, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:Jason W. BrownQing DongBheema R. ParaselliNicholas ScorahJeffrey Alan StaffordMichael B. WallaceHasanthi Wijesekera
A61P 35/00A61P 43/00A61P 25/28A61P 25/16A61P 25/00A61P 29/00A61P 19/02C07D 487/04C07D 471/04C07D 471/14C07D 241/18C07D 401/12
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Claims
exact text as granted — not AI-modified1 - 92 . (canceled)
93 . The compound 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof.
94 . A pharmaceutical composition comprising the compound 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof and a pharmaceutically excipient.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.